GLK Blocking Peptide (Q499)
Référence BP8005c
Conditionnement : 500ug
Marque : Abcepta
Contactez votre distributeur local :
Téléphone : +1 850 650 7790
GLK Blocking Peptide (Q499)
Synthetic peptide
| Primary Accession | Q8IVH8 |
|---|
| Gene ID | 8491 |
|---|---|
| Other Names | Mitogen-activated protein kinase kinase kinase kinase 3, Germinal center kinase-related protein kinase, GLK, MAPK/ERK kinase kinase kinase 3, MEK kinase kinase 3, MEKKK 3, MAP4K3, RAB8IPL1 |
| Target/Specificity | The synthetic peptide sequence is selected from aa 499~518 of HUMAN MAP4K3 |
| Format | Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed. |
| Storage | Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C. |
| Precautions | This product is for research use only. Not for use in diagnostic or therapeutic procedures. |
For Research Use Only. Not For Use In Diagnostic Procedures.
| Name | MAP4K3 (HGNC:6865) |
|---|---|
| Synonyms | RAB8IPL1 |
| Function | Serine/threonine kinase that plays a role in the response to environmental stress. Appears to act upstream of the JUN N-terminal pathway (PubMed:9275185). Activator of the Hippo signaling pathway which plays a pivotal role in organ size control and tumor suppression by restricting proliferation and promoting apoptosis. MAP4Ks act in parallel to and are partially redundant with STK3/MST2 and STK4/MST2 in the phosphorylation and activation of LATS1/2, and establish MAP4Ks as components of the expanded Hippo pathway (PubMed:26437443). |
| Tissue Location | Ubiquitously expressed in all tissues examined, with high levels in heart, brain, placenta, skeletal muscle, kidney and pancreas and lower levels in lung and liver |
Research Areas
- Peptides
- Blocking Peptides